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Abstract
Introduction. Because of the relevant burden of pneumococcal diseases, newborns, 
people at risk and elderly are recommended vaccination but coverage is still low for 
problems in catching them. This study evaluates the proportion of eligible patients seen 
at hospital level in the view of assessing its potential role in vaccination campaigns. 
Methods. This is a retrospective analysis of discharge data of all patients over 49 years 
of age admitted between 2011 and 2013 to “A. Gemelli” teaching hospital. Eligibility for 
pneumococcal vaccination was evaluated based on ICD-9 codes. 
Results. Among 65 047 unique patients, 53.2% were eligible for pneumococcal vaccina-
tion. Most common eligibility criteria were chronic heart diseases, cancer and diabetes. 
Considering also age ≥ 65 as an indication to vaccination, the proportion of eligible 
patients reached 76.8%. The highest number of eligible patients was seen in medical sci-
ences, general surgery, cardiovascular medicine and neurosciences departments. 
Conclusions. Hospital might play an important role in catching patients eligible for 
pneumococcal vaccination because their proportion in the hospital setting is high.
INTRODUCTION
Streptococcus pneumoniae (Sp) is responsible for dif-
ferent diseases: upper and lower respiratory infections 
– i.e. community-acquired pneumonia (CAP) – particu-
larly in elderly, as well as otitis and invasive pneumo-
coccal diseases (IPD), e.g. meningitis and bacteremia, 
especially in children. Sp is a leading cause of infection 
worldwide and in all age groups with elderly and people 
with one or more risk factors showing the highest inci-
dence rates and burden of disease [1]. Chronic medical 
conditions, such as chronic liver disease, chronic heart 
or lung disease, diabetes, asthma, neuromuscular dis-
orders as well as alcohol abuse, smoking, asplenia and 
immunocompromising conditions are the main risk fac-
tors for Sp [2, 3]. Furthermore, accumulation of con-
current at-risk conditions significantly increases the 
risk, independently of age [4-6]. Alongside an increased 
incidence of pneumococcal diseases, patients at risk oc-
cur also higher costs if affected [7].
Sp is responsible of around 30% of all CAP [8, 9]. 
Annual incidence rates of CAP are estimated to range 
from 1.6 to 11.6 per 1000 [10, 11]. Nevertheless, the 
incidence rate is four-times higher in elderly and at risk 
people as compared to younger people [7, 12, 13]. Fur-
thermore, elderly and patients at risk for Sp have also a 
higher mortality [14].
According to the data from the European Centre for 
Disease Prevention and Control, the incidence of IPD 
varies from 0.2 to 13.4 cases per 100 000 population 
across EU/EEA countries [15] with a lethality of 3-35% 
[16, 17]. Italy has reported an incidence rate of con-
firmed cases of 2.41 per 100 000 in 2016. Nevertheless, 
looking only at Regions that pay more attention to notifi-
cation, the incidence increases to 4.58 per 100 000 [18].
Three vaccines are available in order to protect against 
pneumococcal diseases, namely the 13-valent and the 
10-valent pneumococcal conjugate vaccine (PCV10 
and PCV13) and the 23-valent polysaccharide (PPV23). 
They are directed towards different Sp serotypes allow-
ing protection against a part of pneumococcal diseases. 
Currently the PCV13 is included in the National Im-
munization Program (NIP) of some European coun-
tries for vaccination of newborns. The vaccine has been 
also licensed for the use in all age groups for the preven-
tion of CAP and IPD. PCV13 provides elderly and pa-
tients at risk with a new weapon against pneumococcal 
diseases. In fact, the other vaccine used in this target 
population, i.e. the PPV23, has shown some limits [19]. 
PCV13 has been shown to reduce vaccine-type CAP by 
45% and vaccine-type IPD by 75% [20]. Consequently, 
the current Italian NIP recommends vaccinating elderly 
and people at risk [3].
Although the herd effect of the infant vaccination 
programme is meant to indirectly protect unvaccinated 
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people, the burden of preventable pneumococcal dis-
eases remains high, in particular in elderly and people 
at risk [21]. Eventually, vaccinating all groups at risk 
for Sp would have a relevant public health impact [22]. 
In Italy, both the previous (2012-2014) and the current 
(2017-2019) NIP recommends vaccination in new-
borns but also in people at risk for Sp, including elderly 
[3, 23]; the last one recommends a sequential adminis-
tration of PCV13 and PPV23 at 65 years. Following the 
approval of the 2012-2014 NIP, each Region has deliv-
ered its own Immunization Program enclosing details 
on patients at risk for Sp and on vaccination strategies 
to catch them. Lazio Region, at the end of 2012, deliv-
ered the list of conditions at risk for Sp [24]. Neverthe-
less, from 2012 onward, no specific vaccination cam-
paigns were implemented to reach people at risk. Only 
at the end of 2015, the Region has set an age based 
vaccination campaign targeting elderly, which was not 
uniformly implemented. Vaccination coverage among 
elderly is very low with regional estimates ranging from 
0.7% to 50% [25]. Even though data for people at risk 
are not known, it may be expected that vaccination cov-
erage is low also among them. In fact, also international 
evidence shows that, albeit the most of patients with 
pneumococcal diseases have two or more risk factors, 
vaccination coverage in population at risk for Sp is quite 
low, 25-30% overall [26-27].
In the light of this context, the Università Cattolica 
del Sacro Cuore has performed a pilot project together 
with the Fondazione Policlinico Universitario “A. Ge-
melli” aimed at identifying and vaccinating patients at 
risk for Sp in the hospital setting. Within the project, a 
retrospective assessment of the amount of people likely 
eligible to receive pneumococcal vaccination was car-
ried out to characterize their distribution across hospi-
tal wards and departments. This analysis, together with 
the results of the prospective phase of the project on 
vaccination of people at risk in the hospital, which will 
be the objective of a further paper, could be helpful in 
order to inform decision makers about the more suit-
able setting and ways to offer people at risk for Sp with 
the vaccination.
MATERIALS AND METHODS
A retrospective analysis was performed to identify 
patients eligible to receive pneumococcal vaccination 
among all people aged 50 years or older admitted in a 
three-year period between January 1st 2011 and Decem-
ber 31st 2013 to any of the departments of the Fondazi-
one Policlinico Universitario “A. Gemelli”. The hospital 
is located in Lazio, a Region housing, in the three-year 
study period, a mean of 5,520,061 people (9.3% of the 
Italian population) [28]. According to 2013 mission 
report, the Fondazione Policlinico Universitario “A. 
Gemelli”, in the three-year study period, had a mean 
of 1610 hospital beds for acute patients representing 
8% of all regional hospital beds and 13% of the hospital 
beds belonging to the local health authorities in Rome 
[29]. The analysis was carried out on hospital discharge 
records including ordinary admissions, but also inpa-
tient rehabilitation, day hospital and day surgery admis-
sions. For each patient, only the first admission to the 
hospital in the study period was considered, while the 
following admissions were excluded from the analysis. 
Demographic data (gender, date of birth, place of resi-
dence) were used to identify and subsequently exclude 
following admissions. Eligibility criteria were defined 
according to vaccination recommendations proposed 
by the Lazio Region for pneumococcal vaccination 
[24]. These recommendations overlap with national 
ones included in the previous and in the current NIP. 
The following conditions were considered increasing 
the risk for pneumococcal disease: chronic heart, lung 
or liver diseases; alcoholism; diabetes mellitus; cerebro-
spinal fluid fistulas; sickle cell disease and thalassemia; 
congenital or acquired immunodeficiency; anatomic or 
functional asplenia; leukemia, lymphoma or multiple 
myeloma; disseminated cancers; organ or bone marrow 
transplant; clinically significant iatrogenic immunosup-
pression; chronic renal failure, nephrotic syndrome; 
HIV; presence of a cochlear implant. Eligibility criteria 
for pneumococcal vaccination were identified using the 
ICD-9-CM codes that were in force during the study 
period in Italy [30]. For each patient, data reported in 
both primary and secondary diagnoses and in proce-
dures fields were taken into account. Eligible patients 
were defined as those who showed at least one of the 
aforementioned criteria in any of the fields described. 
Since the WHO and the current 2017-2019 NIP rec-
ommend vaccinating against pneumococcal disease all 
subjects aged 65 or older [3, 31], we also stratified the 
results for age class focusing the attention to the age 
group 50-64. Furthermore, a secondary analysis was 
performed considering eligible both people with one 
of the abovementioned criteria and those ≥ 65 years of 
age. In order to assess the potential role of the hospi-
tal as a setting for catching people at risk for Sp, the 
overall proportion of patients eligible for pneumococcal 
vaccination was calculated. The analysis was also strati-
fied by type of hospitalization (ordinary, day hospital 
or day surgery, rehabilitation), department and unit 
of admission. The distribution of patients eligible for 
pneumococcal vaccination by eligibility criteria was also 
analyzed. The statistical analysis was performed using 
the IBM SPSS 22.0 software for Windows.
RESULTS
Between January 1st 2011 and December 31st 2013, a 
total of 120 010 hospital admissions were recorded at 
the Fondazione Policlinico Universitario “A. Gemelli”. 
These admissions corresponded to 65 046 unique pa-
tients (54.2% of the admissions in the study period were 
first admissions). Females were 33 497 (51.5% of the 
sample); median age was 68 (interquartile range: 17), 
and 38 879 (59.8%) patients were aged 65 or above. Of 
the 65 046 unique patients, 46 785 (71.9%) underwent 
an ordinary admission, 18 076 (27.8%) a day hospital 
or a day surgery and 185 (0.3%) were admitted to reha-
bilitation units.
Overall, 34 575 unique patients were eligible for pneu-
mococcal vaccination (53.2% of the sample), with 10 
970 patients showing more than one criteria (16.9% of 
the sample, 31.7% of the eligible subjects). Most com-
monly observed eligibility criteria were chronic heart dis-
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eases (28.3% of the admitted patients), cancer (21.3%), 
diabetes (8.5%) and chronic lung disease (5.0%) (Table 
1). When considering also the age (≥ 65 years of age or 
above) as a criterion for vaccination, the proportion of 
eligible patients raised to 76.8%. In particular, 15 380 
patients (23.6% of the whole sample) showed no other 
vaccination criteria than age. Table 2 reports the figures 
of patients eligible for pneumococcal vaccination be-
cause either ≥ 65 years of age or affected by an at-risk 
condition in each department and single unit.
Of the 38 879 patients aged 65 or above, 23 499 
(60.4%) showed at least one risk condition for Sp as 
compared to 11 076 out of 26 167 among patients un-
der the age of 65 (42.3%) (Table 3). 
Of the 46 785 patients who were seen during an or-
dinary admission, 27 612 were eligible for vaccination 
(59.0%) while of the 18 076 patients seen during a day 
hospital/surgery admission 6848 (37.9%) were eligible. 
One-hundred sixteen out of 185 patients admitted to 
any of the rehabilitation units (62.7%) were also eligible.
In terms of relative frequencies, the departments 
showing the highest proportion of eligible patients were 
as follows: radiology (which includes the radiotherapy 
unit and in which 94.8% of the patients were eligible 
for pneumococcal vaccination), cardiovascular medi-
cine (85.4%) and the public health department (which 
includes the infectious diseases units, 77.4%). In terms 
of absolute numbers, most of the eligible patients were 
observed in the medical sciences department (8485 pa-
tients), the general surgery department (6852), the de-
partment of cardiovascular medicine (5502) and the de-
partment of neurosciences, gerontology and orthopedic 
surgery (4564). With respect to eligible patients aged 
less than 65 years, they were more commonly seen, in 
terms of relative frequencies, in the same departments 
but, as far as absolute numbers are concerned, they 
were highly represented in the departments of obstet-
rics and gynecology (which includes gynecology oncolo-
gy and breast surgery), medical sciences, cardiovascular 
medicine and general surgery.
DISCUSSION
According to our retrospective study, the hospital 
seems a promising setting in order to catch and to 
vaccinate those at risk for pneumococcal diseases, as 
53.2% of the patients aged 50 years or older are eligible 
for vaccination because of the presence of a chronic 
condition or immunodepression. Eligible patients were 
more frequently observed in the cardiovascular medi-
cine department (5502 subjects overall, corresponding 
to 85.4% of the patients admitted to that department), 
the internal medicine units (3659, 81.0%) and the geri-
atric ward (1043, 82.1%). All these accounted for 29.5% 
of eligible patients observed in the over 100 wards, re-
habilitations and day hospital/day surgery units of the 
hospital. Therefore, these departments/units could be 
best suited for identifying patients eligible to receive 
pneumococcal vaccination. Even if radiotherapy ward 
Table 1
Distribution of patients eligible for pneumococcal vaccination according to the Lazio Region recommendations [24]. For each 
condition, the corresponding ICD-9-CM codes used to assess the prevalence are reported
Criteria ICD-9-CM codes N %
Chronic heart disease 394.0-398.99; 401.0-402.91; 412;
413.0-414.9; 416.0-416.9; 423.1-426.89; 427.31-427.32; 428.0-
428.9; 429.0-429.9; 440.0-440.9
18 400 28.3
Disseminated cancers 140.0-195.8; 196.0-198.8; 199.0; 199.1 13 861 21.3
Diabetes mellitus 250.00-250.93 5561 8.5
Chronic lung disease 114.4; 490-496; 500-505; 506.4; 506.9; 508.1; 514-516.9; 517.1-
517.8; 518.1-518.3; 518.83-518.84
3258 5.0
Clinically significant iatrogenic 
immunosuppression
V58.1-V58.12; V58.65; E933.1 2191 3.4
Chronic liver disease 070.22-070.23; 070.32-070.33; 070.44; 070.54; 571; 571.2; 571.40-
571.5; 571.8-571.9
1557 2.4
Chronic renal failure or nephrotic syndrome 585.1-585.9; 403.00-403.91; 404.00-404.93; 405.01; 581.0-581.9; 
V13.03
1341 2.1
Leukemia, lymphoma, multiple myeloma 200.0-208.91 1242 1.9
HIV 042; V08 178 0.3
Alcoholism 291.0-291. 9; 292.2; 303.90-303.93; 305.00-305.03; 357.5; 425.5; 
535.3; 571.0; 980.0; V11.3; V79.1
175 0.3
Anatomic or functional asplenia 41.5; 759.0 76 0.1
Organ or bone marrow transplant 33.50-33.52; 33.6; 37.51; 41.00-41.09; 41.94; 46.97; 50.51; 50.59; 
52.80-52.86; 55.61; 55.69
61 0.1
Presence of a cochlear implant 20.96-20.99; 95.49 54 0.1
Congenital or acquired immunodeficiency 279.0-279.3; 279.8-279.9 33 0.1
Sickle cell disease or thalassemia 282.41-282.49; 282.60-282.69 20 < 0.1
Cerebrospinal fluid fistulas 02.12; 388.61 4 < 0.1
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Table 2
Distribution of patients eligible for pneumococcal vaccination stratified by hospital department and unit
Affected by at least 
one risk condition 
Affected by at least one 
risk condition or ≥ 65 
years of age
Department Unit N total 
admission
N 
eligible
Eligible 
(%)
N 
eligible
Eligible 
(%)
Department of 
medical sciences
Internal and clinical medicine* 1923 1516 78.8 1819 94.6
Internal medicine (and angiology)* 1501 1284 85.5 1439 95.9
Internal medicine (and gastroenterology)* 1090 859 78.8 994 91.2
Endocrinology 1057 768 72.7 935 88.5
Pulmonology 524 485 92.6 513 97.9
Dermatology 296 190 64.2 230 77.7
Obesity diseases 339 265 78.2 315 92.9
Hematology 374 318 85.0 341 91.2
Oncology 664 648 97.6 653 98.3
Day hospital** 4109 2152 52.4 2836 69.0
Total 11 877 8485 71.4 10 075 84.8
Department of 
cardiovascular 
medicine
Cardiology* 2944 2655 90.2 2813 95.6
Cardiac and vascular surgery* 1981 1814 91.6 1919 96.9
Coronary unit 896 593 66.2 755 84.3
Chest pain 393 295 75.1 359 91.3
Day hospital** 228 145 63.6 196 86.0
Total 6442 5502 85.4 6042 93.8
Department of 
obstetrics and 
gynecology
Gynecology and obstetrics* 646 37 5.7 212 32.8
Gynecologic oncology 1620 1287 79.4 1416 87.4
Gynecologic surgery 252 74 29.4 133 52.8
Breast surgery 854 765 89.6 801 93.8
Day hospital** 605 405 66.9 441 72.9
Total 3977 2568 64.6 3003 75.5
Department of 
neurosciences, 
gerontology and 
orthopedic surgery
Neurology* 1668 748 44.8 1247 74.8
Rehabilitation*** 185 116 62.7 176 95.1
Orthopedic surgery and traumatology* 3028 347 11.5 2139 70.6
Geriatric ward 1270 1043 82.1 1243 97.9
Stroke unit 522 322 61.7 429 82.2
Day hospital** 3526 1988 56.4 2795 79.3
Total 10 199 4564 44.7 8029 78.7
Department of 
general surgery
Digestive surgery and proctology* 1159 712 61.4 936 80.8
General surgery (and transplants)* 1047 647 61.8 781 74.6
General surgery (and hepatobiliary surgery)* 945 573 60.6 733 77.6
General surgery (and endocrine surgery)* 1693 342 20.2 846 50.0
Urology 1719 1075 62.5 1418 82.5
Plastic surgery 287 134 46.7 181 63.1
General surgery 904 516 57.1 715 79.1
Thoracic surgery 856 602 70.3 731 85.4
Digestive endoscopy 1798 551 30.6 1344 74.7
Emergency surgery 1755 875 49.9 1395 79.5
Day hospital** 2478 825 33.3 1546 62.4
Total 14 641 6852 46.8 10 626 72.6
Department of 
diseases of the 
head and neck
Neurosurgery* 1380 282 20.4 851 61.7
Ophthalmology and ocular oncology* 562 142 25.3 413 73.5
Otolaryngology 1276 517 40.5 766 60.0
Neuro-traumatology 513 142 27.7 359 70.0
Day hospital** 2650 390 14.7 1721 64.9
Total 6381 1473 23.1 4110 64.4
Department of 
public health
Infectious diseases* 606 448 73.9 509 84.0
Day hospital 169 152 89.9 161 95.3
Total 775 600 77.4 670 86.5
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Table 2
Continued
Affected by at least 
one risk condition 
Affected by at least one 
risk condition or ≥ 65 
years of age
Department Unit N total 
admission
N 
eligible
Eligible 
(%)
N 
eligible
Eligible 
(%)
Emergency 
department
Short stay and post-operative intensive care* 2073 1658 80.0 1896 91.5
Intensive care 577 237 41.1 435 75.4
Total 2650 1895 71.5 2331 88.0
Radiology 
department
Radiotherapy* 485 449 92.6 476 98.1
Day hospital 259 256 98.8 258 99.6
Total 744 705 94.8 734 98.7
Interdepartmental 
day hospital
Day hospital 320 196 61.3 234 73.1
Day surgery 3721 333 8.9 1707 45.9
Total 4041 529 13.1 1941 48.0
Private practice Medical and dental private practice* 3319 1402 42.2 2394 72.1
Total 65 046 34 575 53.2 49 955 76.8
*At least two units combined. **At least two day hospital units combined. ***Includes four units exclusively dedicated to rehabilitation admissions.
Table 3
Distribution of patients eligible for pneumococcal vaccination because affected by at least one at risk condition, stratified by hos-
pital department and unit and age
50-64 years of age 65+ years of age
Department Unit N eligible Eligible (%) N eligible Eligible (%)
Department of medical 
sciences
Internal and clinical medicine* 316 75.2 1037 87.0
Internal medicine (and angiology)* 247 79.9 1200 79.8
Internal medicine (and 
gastroenterology)*
241 71.5 618 82.1
Endocrinology 240 66.3 528 76.0
Pulmonology 94 89.5 391 93.3
Dermatology 72 52.2 118 74.7
Obesity diseases 113 82.5 152 75.2
Hematology 161 83.0 157 87.2
Oncology 246 95.7 402 98.8
Day hospital** 1040 45.0 1112 61.9
Total 2770 60.6 5715 78.2
Department of 
cardiovascular 
medicine
Cardiology* 794 85.8 1861 92.2
Cardiac and vascular surgery* 445 87.8 1369 92.9
Coronary unit 153 52.0 440 73.1
Chest pain 75 68.8 220 77.5
Day hospital** 33 50.8 112 68.7
Total 1500 78.9 4002 88.1
Department of 
obstetrics and 
gynecology
Gynecology and obstetrics* 21 4.6 16 8.4
Gynecologic oncology 681 76.9 606 82.4
Gynecologic surgery 36 23.2 38 39.2
Breast surgery 402 88.4 363 91.0
Day hospital** 216 56.8 189 84.0
Total 1356 58.2 1212 73.6
Department of 
neurosciences, 
gerontology and 
orthopedic surgery
Neurology* 247 37.0 501 50.1
Rehabilitation*** 11 55.0 105 63.6
Orthopedic surgery and 
traumatology*
90 9.2 257 12.5
Geriatric ward 67 71.3 976 83.0
Stroke unit 85 47.8 237 68.9
Day hospital** 195 21.1 1793 69.0
Total 695 24.3 3869 52.8
Continues
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and day hospital and the oncology units only registered, 
respectively, 705 and 648 cases of patients eligible for 
pneumococcal vaccination, these represented nearly all 
their patients (94.8% and 97.6% respectively). Conse-
quently, also such units could play a role in catching 
patients at risk.
When considering also all patients aged 65 or older 
eligible for vaccination even though without risk factors 
for pneumococcal diseases, the proportion of eligible 
patients considerably increased to around 77%. An age-
based vaccination campaign would probably catch el-
derly people outside the hospital setting. However, it 
should be taken into consideration that, in our study, 
more than 40% of subjects younger than 65 years of age 
showed at least one of the eligibility criteria for pneu-
mococcal vaccination. These subjects could be reached 
by their general practitioners but, because of the sup-
posed low level of vaccination coverage, we may sug-
gest that this target could also benefit from a hospital 
based campaign. In fact, the check of vaccination status 
and the inclusion of vaccination in inpatient pathways 
have already been investigated as a solution to increase 
coverage against influenza and Sp [32-34].  The high 
proportion of subjects at risk among people < 65 years 
of age confirms that the hospital may work as a valu-
able setting for increasing vaccination coverage. These 
patients were more commonly seen in different settings 
as compared to the whole group of eligible subjects. In 
fact, they were also frequently observed, in absolute 
terms, in the department of obstetrics and gynecology 
and in the day hospital of the medical sciences depart-
ment. This is probably due to the high prevalence of 
Table 3
Continued
50-64 years of age 65+ years of age
Department Unit N eligible Eligible (%) N eligible Eligible (%)
Department of general 
surgery
Digestive surgery and proctology* 262 54.0 450 66.8
General surgery (and transplants)* 270 50.4 377 73.8
General surgery (and hepatobiliary 
surgery)*
217 50.6 356 69.0
General surgery (and endocrine 
surgery)*
220 20.6 122 19.5
Urology 315 51.1 760 68.9
Plastic surgery 29 21.5 105 69.1
General surgery 156 45.2 360 64.4
Thoracic surgery 192 60.6 410 76.1
Digestive endoscopy 141 23.7 410 34.1
Emergency surgery 215 37.4 660 55.9
Day hospital** 302 24.5 523 42.0
Total 2319 36.6 4533 54.6
Department of 
diseases of the head 
and neck
Neurosurgery* 117 18.1 165 22.5
Ophthalmology and ocular 
oncology*
46 23.6 96 26.2
Otolaryngology 221 30.2 296 54.3
Neuro-traumatology 39 20.2 103 32.2
Day hospital** 172 15.6 218 14.1
Total 595 20.8 878 25.0
Department of public 
health
Infectious diseases* 241 71.3 207 77.2
Day hospital 70 89.7 82 90.1
Total 311 74.8 289 80.5
Emergency 
department
Short stay and post-operative 
intensive care*
414 70.1 1244 83.9
Intensive care 61 30.0 176 47.1
Total 475 59.8 1420 76.5
Radiology department Radiotherapy* 211 95.9 238 89.8
Day hospital 105 99.1 151 98.7
Total 316 96.9 389 93.1
Interdepartmental day 
hospital
Day hospital 112 56.6 84 68.9
Day surgery 111 5.2 222 13.9
Total 223 9.6 306 17.8
Private practice Medical and dental private 
practice*
516 35.8 886 47.2
Total 11 076 42.3 23 499 60.4
*At least two units combined. **At least two day hospital units combined. ***Includes four units exclusively dedicated to rehabilitation admissions
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relatively young women living with (or in follow-up for) 
breast or cervical cancer and of relatively young people 
living with other cancers or diabetes.
Other studies have investigated the prevalence of at 
risk conditions for Sp. Pelton et al. found that 25% of 
adults from 50 to 64 years of age had at least one at-risk 
condition and that 6% had a high-risk condition [35]. 
High-risk conditions, namely those determining im-
munodepression, were found in a similar percentage of 
cases also in a cross-sectional study conducted in Spain 
(5.1%)  [36]. 
Our results depict the frequency of at-risk condi-
tions for Sp in the hospital population and provide a 
picture of the distribution of patients eligible to receive 
pneumococcal vaccination among different units over a 
three-year period. On the other hand, the fact that the 
study considered only one hospital may be considered a 
limit. In fact, other hospitals may admit different kinds 
of patients, which implies that both the proportion of 
eligible patients itself and the distribution of eligibility 
criteria may be different. Furthermore, the results (and 
particularly the absolute numbers of patients eligible 
for pneumococcal vaccination) are influenced by the 
number of hospital beds in each ward. Another limit of 
the study is represented by the use of ICD-9-CM codes 
for detecting people eligible to be vaccinated. This ap-
proach may have led to a misclassification of people, 
possibly underestimating the proportion of candidates 
for vaccination. Another pitfall is represented by the 
lack of information about vaccination status of eligible 
people. As for the strengths, this study is, to the best of 
our knowledge, the first Italian attempt to describe the 
distribution of eligibility for pneumococcal vaccination 
in hospitalized patients. The proportion of candidates 
for pneumococcal vaccination could be extrapolated to 
other tertiary hospitals and considered to inform opti-
mal pneumococcal vaccination strategies. In fact, it is 
important to guarantee vaccination to people at risk for 
pneumococcal diseases and to take advantage of any 
opportunity to do it. The hospital stay or discharge can 
be considered one of these opportunities and this is 
supported by data arising from our study.
CONCLUSION
In order to increase vaccination coverage among peo-
ple at risk for pneumococcal diseases, new strategies 
should be pursued. The hospital may play a relevant role 
in detecting people at risk as this study demonstrates 
that the prevalence of patients eligible for pneumococ-
cal vaccination is quite high in the hospital setting. In 
particular, some departments/units, such as cardiovas-
cular medicine department and internal medicine and 
geriatric units may be an elected place for capturing 
people at risk through counseling, recommendation, 
proposal and offer of the vaccination. 
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